The three receptors to which retatrutide binds function as follows: GLP-1: Enhances satiety, reduces appetite, and promotes insulin secretion, directly supporting weight loss and blood glucose regulation
However, BPC 157 is a therapeutic agent not approved by the FDA, which cites risk of immunogenicity, peptide-related impurities, and limited safety-related information as reasons for banning BPC-157
Some patients might move from, say, weekly injections to monthly injections as maintenance, then eventually to none if possible
Increasingly supported by clinical trials in orthopedic and spinal disorders
More significant results like muscle growth or skin rejuvenation usually develop over weeks to months